Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment

Glioblastoma remains the most common and aggressive primary brain tumor today. Because of the neuroanatomical location of glioblastoma, conventional chemotherapy and radiation therapy have limited efficacy in patients with these tumors. Over the past decade, antitumor immunotherapy has become widesp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	S. V. Timofeeva, A. O. Sitkovskaya, I. A. Novikova, M. A. Ezhova, E. P. Lysenko, O. I. Kit
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2021
Materias:	car-t-терапия глиобластома клинические испытания il-13r α2 her2 egfrviii Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/bc84923f84924863a08fac30e16a46d8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bc84923f84924863a08fac30e16a46d8
record_format	dspace
spelling	oai:doaj.org-article:bc84923f84924863a08fac30e16a46d82021-11-18T08:03:51ZRecent achievements in CAR-T cell immunotherapy for glioblastoma treatment1563-06252313-741X10.15789/1563-0625-RAI-2111https://doaj.org/article/bc84923f84924863a08fac30e16a46d82021-06-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/2111https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XGlioblastoma remains the most common and aggressive primary brain tumor today. Because of the neuroanatomical location of glioblastoma, conventional chemotherapy and radiation therapy have limited efficacy in patients with these tumors. Over the past decade, antitumor immunotherapy has become widespread among modern therapeutic approaches. The importance of immunotherapeutic methods lies in their ability to increase the effectiveness of cancer treatment and prevent relapses by enhancing the systemic and local immune response against tumor cells.One of the most promising directions in modern immunotherapy is CAR-T therapy, or adoptive cell therapy using genetically modified T-lymphocytes. The functional advantage of CAR-T therapy is its ability to genetically modify lymphocytes, leading to their activation in vitro.This review examines the key principles of CAR-T therapy and analyzes the published results of clinical trials for the treatment of glioblastoma using several modifications of CAR-T cells.S. V. TimofeevaA. O. SitkovskayaI. A. NovikovaM. A. EzhovaE. P. LysenkoO. I. KitSPb RAACIarticlecar-t-терапияглиобластомаклинические испытанияil-13r α2her2egfrviiiImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 23, Iss 3, Pp 483-496 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	car-t-терапия глиобластома клинические испытания il-13r α2 her2 egfrviii Immunologic diseases. Allergy RC581-607
spellingShingle	car-t-терапия глиобластома клинические испытания il-13r α2 her2 egfrviii Immunologic diseases. Allergy RC581-607 S. V. Timofeeva A. O. Sitkovskaya I. A. Novikova M. A. Ezhova E. P. Lysenko O. I. Kit Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment
description	Glioblastoma remains the most common and aggressive primary brain tumor today. Because of the neuroanatomical location of glioblastoma, conventional chemotherapy and radiation therapy have limited efficacy in patients with these tumors. Over the past decade, antitumor immunotherapy has become widespread among modern therapeutic approaches. The importance of immunotherapeutic methods lies in their ability to increase the effectiveness of cancer treatment and prevent relapses by enhancing the systemic and local immune response against tumor cells.One of the most promising directions in modern immunotherapy is CAR-T therapy, or adoptive cell therapy using genetically modified T-lymphocytes. The functional advantage of CAR-T therapy is its ability to genetically modify lymphocytes, leading to their activation in vitro.This review examines the key principles of CAR-T therapy and analyzes the published results of clinical trials for the treatment of glioblastoma using several modifications of CAR-T cells.
format	article
author	S. V. Timofeeva A. O. Sitkovskaya I. A. Novikova M. A. Ezhova E. P. Lysenko O. I. Kit
author_facet	S. V. Timofeeva A. O. Sitkovskaya I. A. Novikova M. A. Ezhova E. P. Lysenko O. I. Kit
author_sort	S. V. Timofeeva
title	Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment
title_short	Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment
title_full	Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment
title_fullStr	Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment
title_full_unstemmed	Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment
title_sort	recent achievements in car-t cell immunotherapy for glioblastoma treatment
publisher	SPb RAACI
publishDate	2021
url	https://doaj.org/article/bc84923f84924863a08fac30e16a46d8
work_keys_str_mv	AT svtimofeeva recentachievementsincartcellimmunotherapyforglioblastomatreatment AT aositkovskaya recentachievementsincartcellimmunotherapyforglioblastomatreatment AT ianovikova recentachievementsincartcellimmunotherapyforglioblastomatreatment AT maezhova recentachievementsincartcellimmunotherapyforglioblastomatreatment AT eplysenko recentachievementsincartcellimmunotherapyforglioblastomatreatment AT oikit recentachievementsincartcellimmunotherapyforglioblastomatreatment
_version_	1718422310478675968

Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment

Ejemplares similares